Skip to main content

Advertisement

SpringerLink
Log in

Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Bone metastases are a serious problem in patients with advanced cancer disease and their presence usually signifies serious morbidity prior to the patient’s death. In breast cancer patients the incidence of bone metastasis is observed to be very high at 70 %, as seen during post-mortem examination. Bone metastasis is difficult to diagnose, treat or follow clinically without radiological tools. This study was designed to evaluate the utility of a novel bone resorption marker–serum tartrate-resistant acid phosphatase 5b (TRACP5b) and the bone formation marker such as serum total alkaline phosphatase (ALP), in comparison with whole body skeletal scintigraphy with Technetium99m MDP for the diagnosis of bone metastases (BM) in breast cancer (BC) patients. This study is intended to help the clinician to diagnose bone metastasis without resorting to radiological tools, as they are not cost effective and carry the risk of radiation. Experimental design: Four groups of samples were analysed. 1st group consists 52 normal female (cancer free women), 2nd group consists 38 BC patients without bone metastasis, 3rd group consists 27 breast cancer patients with limited bone metastasis (3 or less than 3 skeletal lesions) and 4th group consists 35 breast cancer patients with extensive bone metastasis (4 or more than 4 skeletal lesions), conformed by whole body skeletal scintigraphy with Technetium99m MDP. One way ANOVA was used to compare serum TRACP5b and serum ALP among these groups. Both serum TRACP5b and serum ALP are not markedly elevated in limited bone metastasis but are strongly elevated in extensive bone metastasis (p < 0.0001). As seen in this study the biochemical bone resorption marker, serum TRACP5b, abnormally increased in extensive bone metastasis of breast cancer patients and can be used as a specific marker for bone metastasis in lieu of radiological tools.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer. 1997;80:1538–45 Medlin.

    Article  CAS  PubMed  Google Scholar 

  2. Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80:1546–56 Cross Ref Medline.

    Article  CAS  PubMed  Google Scholar 

  3. Halleen JM, Alatalo SL, Suominen H. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000;15:1337–45.

    Article  CAS  PubMed  Google Scholar 

  4. Janckila AJ, Takahashi K, Sun SZ. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem. 2001;47:74–80.

    CAS  PubMed  Google Scholar 

  5. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Vaananen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000;15:1337–45.

    Article  CAS  PubMed  Google Scholar 

  6. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci. 2000;113:377–81.

    CAS  PubMed  Google Scholar 

  7. Rosenbrock H, Seifert-Klauss V, Kaspar S, Busch R, Luppa PB. Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med. 2002;40:143–51.

    Article  CAS  PubMed  Google Scholar 

  8. Halleen JM, Ylipahkala H, Alatalo SL. Serum tartrate resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int. 2002;71:20–5.

    Article  CAS  PubMed  Google Scholar 

  9. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell Rand Blumsohn A. Clinical performance of immunoreactive tartrate resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone. 2004;34:187–94.

    Article  CAS  PubMed  Google Scholar 

  10. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ, Vaananen HK. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. ClinChem. 2001;47:597–600.

    CAS  Google Scholar 

  11. Yamagishi N, Takehana K, Kim D, Miura M, Hirata T, Devkota B, et al. Fluorometric Method for Measuring Plasma Tartrate-Resistant Acid Phosphatase Isoform 5b and its application in cattle. J Vet Med Sci. 2009;71(12):1637–42.

    Article  CAS  PubMed  Google Scholar 

  12. Lee HB, Alam MR, Seol JW, Kim NS. Tartrate-resistant acid phosphatase, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in early stages of canine osteoarthritis. Vet Med. 2008;53(4):214–20.

    CAS  Google Scholar 

  13. Coleman RE. Biochemical markers of malignant bone disease. London: Martin Dunitz Ltd.; 2000.

    Google Scholar 

  14. Galasko CS. The significance of occult skeletal metastases, detected by skeletal scintigraphy, in patients with otherwise apparently ‘‘early’’ mammary carcinoma. Br J Surg. 1975;62:694–6.

    Article  CAS  PubMed  Google Scholar 

  15. Sanal SM, Flickinger FW, Caudell MJ. Detection of bone marrow involvement in breast cancer with magnetic resonance imaging. J Clin Oncol. 1994;12:1415–21.

    CAS  PubMed  Google Scholar 

  16. Yeh KA, Fortunato L, Ridge JA. Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann Surg Oncol. 1995;2:319–24.

    Article  CAS  PubMed  Google Scholar 

  17. Coleman RE, Mashiter G, Whitaker KB. Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med. 1988;29:1354–9.

    CAS  PubMed  Google Scholar 

  18. Vogel CL, Schoenfelder J, Shemano I. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995;13:1123–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biotechnology, Nagarjuna University, Guntur, India

    B. K. D. Sarvari

  2. Department of Nuclear Medicine, MNJ Institute of Oncology and Regional Cancer Centre, Red Hills, Hyderabad, India

    D. Sankara Mahadev

  3. Department of Biochemistry, Government General and Chest Hospital, Erragadda, Hyderabad, India

    S. Rupa

  4. P. G. Dept. of Biotechnology & Microbiology, D. N. R. College, P. G. Courses and Research Centre, Bhimavaram, 534202, A. P., India

    S. A. Mastan

Authors
  1. B. K. D. Sarvari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Sankara Mahadev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Rupa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. A. Mastan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. K. D. Sarvari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarvari, B.K.D., Sankara Mahadev, D., Rupa, S. et al. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP. Ind J Clin Biochem 30, 66–71 (2015). https://doi.org/10.1007/s12291-013-0399-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-013-0399-8

Keywords

Search

Navigation